Prevention of Stimulant Induced Euphoria with an Opioid Receptor Antagonist
Technical Report,30 Sep 2012,29 Nov 2016
Massachusetts General Hospital Boston United States
Pagination or Media Count:
The protocol, sponsored by the Department of Defense, is a 6-week study examining whether methylphenidate-induced euphoria can be attenuated by co-administration with naltrexone in medication nave young adults age 18-30 who exhibit a euphoric response to MPH administered on the Drug Feeling Visit. In this double-blind study, subjects will receive MPH and Naltrexone or a placebo to treat their ADHD symptoms over the course of the 6-week trial. Results have not been analyzed so as to not prematurely break the medication blind. A total of 31 subjects completed the Week 3 Drug Feeling Visit, which is the midpoint of the study and the point at which subjects data is useful for analysis. The findings from this study provide support for the concept of combining opioid receptor antagonists with stimulants to provide and effective stimulant formulation with less abuse potential. This study has, to date, resulted in one accepted manuscript, two accepted abstracts, and one additional manuscript in progress.
- Medicine and Medical Research